Table 4. Efficacy subgroup analyses in different tumor types.
| PFS | OS | ORR | |||||||
|---|---|---|---|---|---|---|---|---|---|
| N. of studies | Log HR (95% CI) | I2 | N. of studies | Log HR (95% CI) | I2 | N. of studies | RR (95% CI) | I2 | |
| Metastatic Colorectal Cancer | |||||||||
| BV dose | |||||||||
| 2.5 mg/kg | 9 | 0.86 (0.79–0.94) | 84.8 | 8 | 0.94 (0.87–1.01) | 65.1 | 5 | 1.22 (0.89–1.67) | 80.4 |
| 5 mg/kg | 2 | 0.81 (0.75–0.87) | 0 | 2 | 0.89 (0.82–0.95) | 0 | 2 | 2.15 (1.15–3.99) | 40.7 |
| Chemotherapy regimen | |||||||||
| Platinum | 6 | 0.91 (0.83–1.01) | 84.7 | 6 | 0.95 (0.87–1.04) | 75.1 | 3 | 1.12 (0.49–2.55) | 91.6 |
| Non-platinum | 4 | 0.78 (0.74–0.82) | 0 | 3 | 0.90 (0.83–0.98) | 0 | 4 | 1.51 (1.12–2.04) | 28.0 |
| Age (years) | |||||||||
| 50–55 | 1 | 0.76 (0.68–0.85) | 0 | - | - | - | 1 | 2.05 (1.14–3.67) | - |
| 56–60 | 4 | 0.91 (0.78–1.07) | 91.2 | 4 | 0.94 (0.81–1.08) | 80.5 | 3 | 1.02 (0.80–1.38) | 82.3 |
| 61–65 | 2 | 0.83 (0.79–0.87) | 0 | 2 | 0.90 (0.86–0.94) | 0 | 1 | 2.64 (1.72–4.07) | - |
| >66 | 1 | 0.82 (0.74–0.90) | 0 | 1 | 0.95 (0.85–1.06) | - | - | - | - |
| Median Follow-up (months) | |||||||||
| 6–12 | 1 | 0.85 (0.80–0.90) | 0 | 1 | 0.91 (0.85–0.98) | - | - | - | - |
| 13–24 | 3 | 0.76 (0.71–0.81) | 0 | 2 | 0.83 (0.72–0.96) | 0 | 2 | 1.53 (0.88–2.65) | 51.5 |
| 25–36 | 5 | 0.86 (0.80–0.94) | 58.6 | 5 | 0.92 (0.86–0.98) | 35.1 | 3 | 1.12 (0.49–2.55) | 91.6 |
| >37 | 1 | 1.07 (0.99–1.16) | - | 1 | 1.11 (1.01–1.22) | 0 | - | - | - |
| Median duration of therapy (weeks) | |||||||||
| <12 | - | - | - | — | - | - | - | - | - |
| 12–24 | 2 | 0.93 (0.70–1.23) | 96.2 | 2 | 0.99 (0.79–1.24) | 93.0 | 1 | 2.64 (1.72–4.07) | - |
| 25–36 | 3 | 0.84 (0.74–0.94) | 81.3 | 2 | 0.95 (0.90–1.00) | 0 | 2 | 1.33 (0.63–2.79) | 84.4 |
| >37 | 1 | 0.76 (0.70–0.83) | - | 1 | 0.84 (0.71–0.99) | - | 1 | 1.29 (1.08–1.53) | - |
| Time points of response assessment (weeks) | |||||||||
| 6 | 4 | 0.84 (0.75–0.94) | 78.3 | 4 | 0.91 (0.83–1.00) | 43.5 | 4 | 1.13 (0.82–1.54) | 81.9 |
| 8–12 | 3 | 0.79 (0.74–0.84) | 0 | 2 | 0.88 (0.82–0.94) | 0 | 2 | 2.59 (1.77–3.80) | 0 |
| 24 | 1 | 1.07 (0.99–1.16) | - | 1 | 1.11 (1.01–1.22) | - | - | - | - |
| Metastatic NSCLC | |||||||||
| BV dose | |||||||||
| 2.5 mg/kg | 2 | 0.87 (0.80–0.94) | 0 | 1 | 0.90 (0.69–1.18) | - | - | - | - |
| 5 mg/kg | 7 | 0.85 (0.81–0.89) | 25.3 | 6 | 0.94 (0.90–0.99) | 0 | 5 | 1.60 (1.37–87) | 9.4 |
| Chemotherapy regimen | |||||||||
| Platinum | 8 | 0.86) 0.83–0.90) | 5.3 | 6 | 0.92 (0.87–0.97) | 0 | 3 | 1.57 (1.32–1.86) | 18.6 |
| Non-platinum | 1 | 0.81 (0.75–0.88) | 0 | 1 | 0.99 (0.91–1.07) | - | 1 | 1.99 (1.17–3.37) | - |
| Age (years) | |||||||||
| 50–55 | - | - | - | - | - | - | - | - | - |
| 56–60 | 3 | 0.89 (0.83–0.95) | 20.3 | 1 | 1.07 (0.83–1.36) | - | 3 | 1.51 (1.26–1.80) | 12.8 |
| 61–65 | 3 | 0.81 (0.75–0.87) | 0 | 3 | 0.98 (0.91–1.05) | 0 | 2 | 1.98 (1.43–2.74) | 0 |
| >66 | - | - | - | - | - | - | - | - | - |
| Median Follow-up (months) | |||||||||
| 6–12 | 2 | 0.85 (0.74–0.97) | 39.3 | 1 | 1.07 (0.83–1.36) | - | 2 | 1.47 (1.04–2.06) | 57.2 |
| 13–24 | 4 | 0.82 (0.79–0.86) | 0 | 4 | 0.93 (0.88–0.98) | 2.3 | 1 | 1.99 (1.17–3.37) | - |
| 25–36 | - | - | - | - | - | - | - | - | - |
| >37 | - | - | - | - | - | - | - | - | - |
| Median duration of therapy (weeks) | |||||||||
| <12 | - | - | - | - | - | - | - | - | - |
| 12–24 | 5 | 0.84 (0.80–0.88) | 0 | 4 | 0.92 (0.87–0.98) | 0 | 3 | 1.59 (1.22–2.07) | 44.4 |
| 25–36 | - | - | - | - | - | - | - | - | - |
| >37 | 1 | 0.83 (0.65–1.06) | - | 1 | 0.86 (0.68–1.09) | - | - | - | - |
| Time points of response assessment (weeks) | |||||||||
| 6 | 6 | 0.82 (0.78–0.86) | 0 | 6 | 0.94 (0.90–0.99) | 0 | 3 | 1.64 (1.14–2.35) | 52.6 |
| 8–12 | 1 | 0.88 (0.81–0.96) | - | - | - | - | 1 | 1.69 (1.31–2.19) | - |
| 24 | - | - | - | - | - | - | - | - | - |
| Metastatic Breast Cancer | |||||||||
| BV dose | |||||||||
| 2.5 mg/kg | 2 | 0.91 (0.83–0.98) | 0 | 1 | 1.02 (0.91–1.14) | - | 2 | 1.18 (1.01–1.37) | 0 |
| 5 mg/kg | 6 | 0.87 (0.82–0.92) | 59.8 | 6 | 0.97 (0.93–1.01) | 0 | 7 | 1.42 (1.30–1.55) | 0 |
| Chemotherapy regimen | |||||||||
| Platinum | 6 | 0.86 (0.82–0.90) | 36.6 | 6 | 0.97 (0.93–1.01) | 0 | 5 | 1.34 (1.20–1.49) | 32.0 |
| Non-platinum | 2 | 0.92 (0.79–1.06) | 78.9 | 2 | 0.99 (0.88–1.12) | 47.5 | 2 | 1.43 (1.21–1.68) | 0 |
| Age (years) | |||||||||
| 50–55 | 7 | 0.89 (0.85–0.93) | 31.0 | 5 | 0.98 (0.93–1.03) | 0 | 4 | 1.31 (1.19–1.44) | 0 |
| 56–60 | 2 | 0.82 (0.77–0.87 | 11.8 | 2 | 0.96 (0.90–1.03) | 0 | 3 | 1.51 (1.24–1.85) | 29.5 |
| 61–65 | - | - | - | - | - | - | - | - | - |
| >66 | - | - | - | - | - | - | - | - | - |
| Median Follow-up (months) | |||||||||
| 6–12 | - | - | - | - | - | - | - | - | - |
| 13–24 | 3 | 0.89 (0.82–0.95) | 60.4 | 3 | 1.07 (0.83–1.36) | 0 | 3 | 1.38 (1.22–1.55) | 0 |
| 25–36 | 2 | 0.91 (0.85–0.98) | 0 | 2 | 0.97 (0.93–1.00) | 2.3 | 2 | 1.41 (0.93–2.12) | 86.1 |
| >37 | 1 | 0.80 (0.75–0.86) | - | 1 | 0.93 (0.88–0.98) | - | - | - | - |
| Median duration of therapy (weeks) | |||||||||
| <12 | - | - | - | - | - | - | - | - | - |
| 12–24 | - | - | - | - | - | - | - | - | - |
| 25–36 | 4 | 0.85 (0.80–0.90) | 40.5 | 3 | 0.92 (0.87–0.98) | 0 | 4 | 1.46 (1.25–1.71) | 15.9 |
| >37 | 1 | 0.92 (0.83–1.01) | 0 | - | - | - | - | - | - |
| Time points of response assessment (weeks) | |||||||||
| 6 | 2 | 0.94 (0.85–1.03) | 53.2 | 2 | 0.99 (0.84–1.47) | 28.9 | 2 | 1.42 (1.15–1.75) | 0 |
| 8–12 | 5 | 0.87 (0.82–0.92) | 45.9 | 3 | 0.94 (0.90–0.99) | 0 | 4 | 1.38 (1.12–1.71) | 62.9 |
| 24 | - | - | - | - | - | - | - | - | - |
Abbreviations: PFS: progression free survival; OS: overall survival; ORR: overall response rate; HR: hazard ratio; RR: relative risk; BV: bevacizumab; NSCLC: non-small cell lung cancer.